Biodesix (BDSX) SEC Filings: History & Chart

Biodesix, Inc.(BDSX)

Medical - Diagnostics & Research · Louisville, CO

$28.06-1.00 (-3.44%)

Delayed quote: Oct 6, 2026, 11:04 AM EDT

About Biodesix, Inc.

Biodesix, Inc. is a data-driven diagnostic solutions provider operating across the United States. Its primary focus includes a comprehensive suite of blood-based lung tests, marketed as the Nodify Lung Nodule Risk Assessment (which includes Nodify XL2 and Nodify CDT). These assessments enable clinicians to evaluate the risk of lung cancer in patients with suspicious nodules, aiding in the reclassification of malignancy risk and guiding appropriate treatment pathways. Beyond risk assessment, Biodesix offers additional lung cancer diagnostics such as GeneStrat ddPCR, which detects specific tumor mutations, and VeriStrat, which gauges the patient's immune system status. Both are crucial for establishing prognosis and informing treatment plans. Another offering is the GeneStrat NGS (Next-Generation Sequencing) test, a rapid, blood-based sequencing solution providing results within 72 hours. Through a partnership with Bio-Rad Laboratories, Inc., Biodesix also provides COVID-19 testing services under its Biodesix WorkSafe program, featuring the Bio-Rad SARS-CoV-2 ddPCR test and the Platelia SARS-CoV-2 Total Ab test, an antibody assay for detecting a B-cell immune response indicating recent or prior infection. Furthermore, the company extends its expertise to biopharmaceutical companies, offering diagnostic and clinical research services, alongside clinical trial testing. It also actively discovers, develops, and commercializes companion diagnostics. Originally incorporated as Elston Technologies, Inc. in 2005, Biodesix, Inc. maintains its headquarters in Boulder, Colorado.

Louisville, CO

334 employees

www.biodesix.com

Healthcare / Medical - Diagnostics & Research

Sector: Healthcare
Industry: Medical - Diagnostics & Research
CEO: Scott Hutton

View full financials

Form	Filing Date	Accepted	Document
4	Oct 2, 2026	Oct 2, 2026	View filing
4	Aug 13, 2026	Aug 13, 2026	View filing
4	Aug 12, 2026	Aug 12, 2026	View filing
10-Q	Aug 5, 2026	Aug 5, 2026	View filing
8-K	Aug 5, 2026	Aug 5, 2026	View filing
4	Jul 2, 2026	Jul 2, 2026	View filing
SC 13G	Jun 18, 2026	Jun 18, 2026	View filing
424B3	Jun 1, 2026	May 29, 2026	View filing
EFFECT	May 29, 2026	Jun 1, 2026	View filing
S-3	May 21, 2026	May 21, 2026	View filing
8-K	May 20, 2026	May 20, 2026	View filing
SC 13G/A	May 15, 2026	May 15, 2026	View filing
SC 13G/A	May 8, 2026	May 8, 2026	View filing
10-Q	May 4, 2026	May 4, 2026	View filing
8-K	May 4, 2026	May 4, 2026	View filing
SC 13G	Apr 28, 2026	Apr 28, 2026	View filing
ARS	Apr 9, 2026	Apr 9, 2026	View filing
DEFA14A	Apr 9, 2026	Apr 9, 2026	View filing
DEF 14A	Apr 9, 2026	Apr 9, 2026	View filing
4	Apr 2, 2026	Apr 2, 2026	View filing
10-K	Feb 26, 2026	Feb 26, 2026	View filing
8-K	Feb 26, 2026	Feb 26, 2026	View filing
4	Feb 23, 2026	Feb 23, 2026	View filing
4	Feb 23, 2026	Feb 23, 2026	View filing
4	Feb 23, 2026	Feb 23, 2026	View filing
4	Feb 23, 2026	Feb 23, 2026	View filing
4	Feb 23, 2026	Feb 23, 2026	View filing
4	Feb 11, 2026	Feb 11, 2026	View filing
4	Feb 11, 2026	Feb 11, 2026	View filing
4	Feb 11, 2026	Feb 11, 2026	View filing

SEC Filings

Recent Filings